Summary of Conference Call Notes Company Overview - The company discussed its performance and developments related to its products, particularly focusing on CM310 (Sikukiyu monoclonal antibody), CM512 (TSLP/IL-13 dual antibody), and CMG901 (Claudin 18.2 ADC) [2][3][4][8]. Key Points Industry and Product Performance - **CM310 (Sikukiyu monoclonal antibody)**: - Achieved sales of 310 million RMB in 2025, a 77.2% increase year-on-year [3]. - Entered the national medical insurance list in January 2026, significantly boosting hospital access [4][5]. - Expected to be available in nearly 1,000 hospitals by the end of 2026, with over 40% access achieved [5]. - **CM512 (TSLP/IL-13 dual antibody)**: - Positioned as an upgraded version of CM310, with a reduced administration frequency of 2-4 injections per year [2][8]. - Clinical data for nasal polyps expected to be read out ahead of schedule in June-July 2026 [8][16]. - **CMG901 (Claudin 18.2 ADC)**: - Licensed to AstraZeneca, with global filing for second-line gastric cancer expected in H2 2026 [2][8]. - The project has entered first-line combination therapy trials, with over 2,500 patients planned for global clinical trials [10][17]. Financial Performance - Total revenue for 2025 was 720 million RMB, a 67% increase year-on-year, with product sales contributing 310 million RMB [3][11]. - The company raised 860 million HKD through H-share placement, maintaining a cash reserve of nearly 2 billion RMB by the end of 2025 [3][11]. - R&D investment remained stable at 720 million RMB, with a net loss of 500 million RMB for 2025 [11]. Production Capacity and Cost Management - The company is expanding its production capacity with the ND4 stainless steel production line, set to be operational by March 2026, which will significantly reduce costs [6][11]. R&D Pipeline and Strategic Initiatives - The company is diversifying its R&D beyond antibody drugs, with advancements in ADC, small nucleic acids, and PROTAC platforms [7][19]. - CM336 (BCMAxCD3) has shown over 90% overall response rate (ORR) and 75% complete response (CR) in multiple myeloma, with a strategic partnership with Gilead to enhance global market access [9][12]. Future Milestones - Key R&D milestones for 2026 include: - Submission of CM310 for adolescent moderate to severe atopic dermatitis [11]. - Data readout for CM512 in nasal polyps expected in mid-2026 [11]. - Initiation of clinical trials for CM313 and CMG901 [11][17]. Market Strategy and Competitive Positioning - The company aims to leverage its first-mover advantage in the dermatology field while expanding into respiratory and nasal indications [23][24]. - CM512 is not expected to be the first approved indication; instead, the focus will be on asthma and COPD to avoid pricing pressures from a large patient population [24][25]. Clinical Data and Academic Engagement - The company plans to present key clinical data at major academic conferences in 2026, including results for CM-518 and CM-310 [27]. Patient Engagement and Market Dynamics - Following the inclusion of CM310 in the national insurance list, patient adherence (DOT) has increased, with potential for over 15 treatment cycles observed in chronic patients [28]. Conclusion The company is positioned for significant growth with a robust pipeline, strategic partnerships, and a focus on expanding its market presence while maintaining financial stability and operational efficiency.

Pharmaceutical Sector - Changchun Gaoxin's new drug for treating developmental disorders in boys has significantly impacted its stock price, but the company has stated that the project is still in the early stages [1] - Boya Bio plans to focus its future research on gene therapy and antibody drugs [1] Robotics Sector - Liard's robotics business falls under the AI and spatial computing segment, contributing approximately 5% to total revenue [1] - Liard has established partnerships with several well-known domestic and international robotics manufacturers [1] - Sanrui Technology's intelligent sensor chips are not applied in humanoid robots [1] Battery Sector - Wanshun New Materials has begun small-scale supply of aluminum foil for high-capacity batteries [1] Chemical Sector - Yahua Group reports that the current export ban in Zimbabwe will not affect its normal production and operations [1] - Dongyue Silicon Material is actively engaging the market with its liquid glue products [1]

Company Overview - The company, Shiyao Innovation, submitted its prospectus to the Hong Kong Stock Exchange on December 10, 2025, aiming for a mainboard listing, with CITIC Securities as the sole sponsor [1] - Shiyao Innovation was spun off from Shiyao Group and was listed on the A-share market in March 2019, with a market capitalization of 47.5 billion RMB as of December 11 [1] - The company focuses on biopharmaceuticals, functional raw materials, and health foods, reporting revenues of 1.98 billion RMB in 2024 and a net loss of 304 million RMB [1] Financial Performance - For the first seven months of 2025, the company reported revenues of 1.24 billion RMB, a year-on-year increase of 8.74%, with a net loss of 226 million RMB [8] - The gross profit margin for the first seven months of 2025 was 38.27%, while the R&D expense ratio was approximately 42.67% [8] - The company has seen a significant increase in net loss year-on-year, with a 483.69% increase in net loss for the first seven months of 2025 compared to the previous year [8] Product and Market Focus - The company has expanded its main business into the biopharmaceutical sector by acquiring control of Giant Rock Biotech in 2024, marking a strategic shift in its development [1] - Shiyao Innovation is the largest producer of synthetic caffeine globally from 2020 to 2024, supplying major companies like Coca-Cola, PepsiCo, and Red Bull [1] - The company is strategically focusing on antibody drugs, ADCs, and mRNA vaccines, with a strong pipeline of 15 drugs in clinical or late-stage development, including 9 ADCs and 1 mRNA vaccine [3][5] Industry Insights - The global antibody drug market is projected to grow from $163.8 billion in 2019 to $254.3 billion in 2024, with a compound annual growth rate (CAGR) of 9.2% [10] - The synthetic caffeine market is expected to grow from $391.4 million in 2019 to $578.5 million in 2024, with a CAGR of 8.1% [19] - The company holds a 51.5% market share in China's synthetic caffeine market as of 2024 [20]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of CSPC Innovation Pharmaceutical Co., Ltd. 石藥創新製藥股份有限公司 (the "Company") (A joint stock company incorporated in the Pe ...

Group 1 - The company reported a revenue of 4.288 billion and a net profit of 775 million for the first half of the year, representing a year-on-year growth of 16.97% [1] - The main business of the company focuses on the research, production, and sales of pharmaceuticals, with an emphasis on innovation-driven development [1] - The company has 83 projects in its research pipeline, including 31 innovative drugs, and is focusing on cardiovascular, neurological, and digestive diseases [1] Group 2 - The company is advancing the development of modern traditional Chinese medicine, with 29 projects currently in clinical trials, including 21 in phases II and III [2] - The company has received approval for the production of Anshen Dripping Pills and is conducting clinical trials for various other traditional Chinese medicine products [2] - The company has expanded the indication for Puyouke from acute ST-segment elevation myocardial infarction to acute ischemic stroke, demonstrating its effectiveness and safety [2] Group 3 - The company adheres to the "no-walled research institute" concept, enhancing external collaborations and integrating advanced technological resources [3] - The company has established a complete system from preclinical to clinical research, supported by a highly educated and specialized talent team [3] - The company has developed four core research capabilities, including drug property verification, clinical translation, international registration, and integrated project management [3]

Core Insights - The article highlights the rapid growth of the ophthalmic drug market in China, with Kanghong Pharmaceutical's product "Langmu" breaking the monopoly of imported drugs and achieving significant sales [1][4][5] - Kanghong Pharmaceutical has established itself as a leader in the innovative drug sector, focusing on ophthalmology, mental health, and oncology, with a strong emphasis on innovation and quality [3][7][12] Company Performance - In 2024, Kanghong Pharmaceutical's biopharmaceutical business revenue reached 2.343 billion yuan, a year-on-year increase of 20.98%, accounting for 52.61% of total revenue [1] - The sales of Kanghong's product, Kangbaxip, reached 500 million yuan in 2023, capturing 36% of the market share [1] - The company has maintained a consistent growth trajectory for Kangbaxip over the past 11 years, with over 2.5 million injections administered [1][5] Market Dynamics - The global ophthalmic drug market is projected to reach $83.477 billion by 2031, with a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031 [3] - China has over 40 million patients with retinal diseases, with more than 3 million new patients added annually, indicating a significant market opportunity [4][8] Innovation and R&D - Kanghong Pharmaceutical has a comprehensive R&D strategy, with 21 marketed drugs, 10 of which are exclusive and 17 included in the national medical insurance directory [3][12] - The company is actively developing gene therapy and antibody drugs, with two ophthalmic products in clinical trials aimed at reducing injection frequency for patients [9][10] Production Capacity - Kanghong is investing in building production capabilities for gene therapy drugs, establishing a full-chain capability from R&D to commercialization [12][13] - The company has constructed GMP-compliant production bases in Beijing and Chengdu, enhancing its manufacturing capabilities for biopharmaceuticals [13]